Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD


Diabetes research and publications often focus on the lifestyle–related type 2 diabetes epidemic, and forget about type 1 – a chronic condition caused by a malfunctioning pancreas. However, new research is embracing recent technological advances to improve the quality of life for children and adults living with type 1 diabetes, by looking into generating an artificial or bionic pancreas.

Read more

Stomach cancer is the third biggest cancer killer worldwide, with new therapies proving difficult to develop due to the diversity of the disease, and a classification system which has limited clinical use. However, newly published research has broken down stomach cancer into 4 bite sized portions, each with their own distinguishing features, with the hope of improving patient classification and guiding the use of targeted therapies.

Read more

Due to increasing obesity levels, inactivity, and an aging population worldwide the prevalence of type 2 diabetes has reached epidemic proportions. The World Health Organization reports that 347 million people globally have diabetes, with type 2 accounting for 90% of cases. Whilst type 2 diabetes prevalence rates have been increasing in the US recently, (from 25.8 million in 2010 to 29.1 million in 2012) mortality rates for diabetics have fallen due to improved care and antidiabetic therapies. Due to these changes in prevalence and mortality the CDC decided to re-examine the lifetime risk of developing diabetes in the US, with some shocking probabilities revealed.

Read more

Immunotherapy is at the forefront of oncology research, with many companies focusing on the same specific targets in multiple cancer types. The race has been on for the first US approval of an anti-PD-1 agent, and Merck have proved victorious with the FDA saying yes to Keytruda (pembrolizumab) in advanced melanoma just last week.

Read more

Historically in oncology, the therapeutic use of radiation has been based on its ability to kill cells and selectively target tumor tissue. More recently a paradigm shift has been seen - combining radiotherapy with up and coming immunotherapies to exploit the benefits of each treatment and extend patient survival. Recent preclinical research in this area has shown that triple therapy (with focal radiation boosting treatment with two immunotherapeutic agents) has had particularly impressive survival results in glioblastoma.

Read more

Personalized medicine is the future of cancer therapy, and many techniques are being used to drive forward research in this area. Patient-derived xenograft (PDX) models are at the forefront of personalized medicine research in human surrogate trials, but other approaches to using PDX are also being pioneered which may not bring the full patient benefit to everyone.

Read more